Publication:
First successful trial of preimplantation genetic diagnosis for pantothenate kinase-associated neurodegeneration

dc.contributor.authorObjoon Trachooen_US
dc.contributor.authorChonthicha Satirapoden_US
dc.contributor.authorBhakbhoom Panthanen_US
dc.contributor.authorMatchuporn Sukpraserten_US
dc.contributor.authorAngkana Charoenyingwattanaen_US
dc.contributor.authorWasun Chantratitaen_US
dc.contributor.authorWicharn Choktanasirien_US
dc.contributor.authorSuradej Hongengen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-12-21T06:58:18Z
dc.date.accessioned2019-03-14T08:03:03Z
dc.date.available2018-12-21T06:58:18Z
dc.date.available2019-03-14T08:03:03Z
dc.date.issued2017-01-01en_US
dc.description.abstract© 2016, Springer Science+Business Media New York. Purpose: We aim to present a case of a healthy infant born after intracytoplasmic sperm injection-in vitro fertilization (ICSI-IVF) with a preimplantation genetic diagnosis (PGD) for pantothenate kinase-associated neurodegeneration (PKAN) due to PANK2 mutation. Methods: ICSI-IVF was performed on a Thai couple, 34-year-old female and 33-year-old male, with a family history of PKAN in their first child. Following fertilization, each of the embryos were biopsied in the cleavage stage and subsequently processed for whole-genome amplification. Genetic status of the embryos was diagnosed by linkage analysis and direct mutation testing using primer extension-based mini-sequencing. Comprehensive chromosomal aneuploidy screening was performed using a next-generation sequencing-based strategy. Results: Only a single cycle of ICSI-IVF was processed. There were seven embryos from this couple—two were likely affected, three were likely carriers, one was likely unaffected, and one failed in target genome amplification. Aneuploidy screening was performed before making a decision on embryo transfer, and only one unaffected embryo passed the screening. That embryo was transferred in a frozen thawed cycle, and the pregnancy was successful. The diagnosis was confirmed by amniocentesis, which presented with a result consistent with PGD. At 38 weeks of gestational age, a healthy male baby was born. Postnatal genetic confirmation was also consistent with PGD and the prenatal results. At the age of 24 months, the baby presented with normal growth and development lacking any neurological symptoms. Conclusions: We report the first successful trial of PGD for PKAN in a developing country using linkage analysis and mini-sequencing in cleavage stage embryos.en_US
dc.identifier.citationJournal of Assisted Reproduction and Genetics. Vol.34, No.1 (2017), 109-116en_US
dc.identifier.doi10.1007/s10815-016-0833-yen_US
dc.identifier.issn15737330en_US
dc.identifier.issn10580468en_US
dc.identifier.other2-s2.0-84994201324en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/42025
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84994201324&origin=inwarden_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleFirst successful trial of preimplantation genetic diagnosis for pantothenate kinase-associated neurodegenerationen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84994201324&origin=inwarden_US

Files

Collections